WO2006030907A1 - 網膜保護剤 - Google Patents
網膜保護剤 Download PDFInfo
- Publication number
- WO2006030907A1 WO2006030907A1 PCT/JP2005/017170 JP2005017170W WO2006030907A1 WO 2006030907 A1 WO2006030907 A1 WO 2006030907A1 JP 2005017170 W JP2005017170 W JP 2005017170W WO 2006030907 A1 WO2006030907 A1 WO 2006030907A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- retinal
- retina
- sulforafuan
- pharmaceutical composition
- sulforan
- Prior art date
Links
- 210000001525 retina Anatomy 0.000 title claims abstract description 47
- 239000003223 protective agent Substances 0.000 title claims abstract description 24
- 235000013305 food Nutrition 0.000 claims abstract description 41
- 230000001681 protective effect Effects 0.000 claims abstract description 20
- 239000004480 active ingredient Substances 0.000 claims abstract description 8
- 230000002207 retinal effect Effects 0.000 claims description 63
- 238000000034 method Methods 0.000 claims description 35
- 239000008194 pharmaceutical composition Substances 0.000 claims description 31
- 208000017442 Retinal disease Diseases 0.000 claims description 16
- 208000002780 macular degeneration Diseases 0.000 claims description 16
- 230000002633 protecting effect Effects 0.000 claims description 15
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 12
- 241000124008 Mammalia Species 0.000 claims description 9
- 208000007014 Retinitis pigmentosa Diseases 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 7
- 230000007850 degeneration Effects 0.000 claims description 3
- 230000003449 preventive effect Effects 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims description 2
- SUVMJBTUFCVSAD-UHFFFAOYSA-N sulforaphane Chemical compound CS(=O)CCCCN=C=S SUVMJBTUFCVSAD-UHFFFAOYSA-N 0.000 abstract description 10
- SUVMJBTUFCVSAD-JTQLQIEISA-N 4-Methylsulfinylbutyl isothiocyanate Natural products C[S@](=O)CCCCN=C=S SUVMJBTUFCVSAD-JTQLQIEISA-N 0.000 abstract description 5
- 229960005559 sulforaphane Drugs 0.000 abstract description 5
- 235000015487 sulforaphane Nutrition 0.000 abstract description 5
- 239000000203 mixture Substances 0.000 abstract description 2
- 241000699670 Mus sp. Species 0.000 description 29
- 210000004027 cell Anatomy 0.000 description 27
- 241000196324 Embryophyta Species 0.000 description 22
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 17
- 102100036407 Thioredoxin Human genes 0.000 description 17
- 238000004458 analytical method Methods 0.000 description 14
- 241000699666 Mus <mouse, genus> Species 0.000 description 12
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- 239000011780 sodium chloride Substances 0.000 description 11
- 238000001262 western blot Methods 0.000 description 11
- 239000000047 product Substances 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 239000003463 adsorbent Substances 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 206010057430 Retinal injury Diseases 0.000 description 8
- 230000002354 daily effect Effects 0.000 description 8
- 239000002904 solvent Substances 0.000 description 8
- 239000000284 extract Substances 0.000 description 7
- 238000000605 extraction Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 238000007912 intraperitoneal administration Methods 0.000 description 7
- 235000011299 Brassica oleracea var botrytis Nutrition 0.000 description 6
- 240000003259 Brassica oleracea var. botrytis Species 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 208000003464 asthenopia Diseases 0.000 description 6
- 230000030833 cell death Effects 0.000 description 6
- 210000003855 cell nucleus Anatomy 0.000 description 6
- 210000005081 epithelial layer Anatomy 0.000 description 6
- 235000019441 ethanol Nutrition 0.000 description 6
- 239000000419 plant extract Substances 0.000 description 6
- 230000006378 damage Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 210000001508 eye Anatomy 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 240000007124 Brassica oleracea Species 0.000 description 4
- 235000003899 Brassica oleracea var acephala Nutrition 0.000 description 4
- 235000017647 Brassica oleracea var italica Nutrition 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 4
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 4
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 4
- 102000003992 Peroxidases Human genes 0.000 description 4
- 238000009395 breeding Methods 0.000 description 4
- 230000001488 breeding effect Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 108040007629 peroxidase activity proteins Proteins 0.000 description 4
- 239000002504 physiological saline solution Substances 0.000 description 4
- 239000000790 retinal pigment Substances 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 238000011870 unpaired t-test Methods 0.000 description 4
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 102000002933 Thioredoxin Human genes 0.000 description 3
- 210000005252 bulbus oculi Anatomy 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 230000037406 food intake Effects 0.000 description 3
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 3
- 230000035784 germination Effects 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000003834 intracellular effect Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000011259 mixed solution Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 210000005157 neural retina Anatomy 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 150000002978 peroxides Chemical class 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 238000011002 quantification Methods 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 108060008226 thioredoxin Proteins 0.000 description 3
- 229940094937 thioredoxin Drugs 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- 201000004569 Blindness Diseases 0.000 description 2
- 235000011293 Brassica napus Nutrition 0.000 description 2
- 235000011301 Brassica oleracea var capitata Nutrition 0.000 description 2
- 235000001169 Brassica oleracea var oleracea Nutrition 0.000 description 2
- 235000012905 Brassica oleracea var viridis Nutrition 0.000 description 2
- 240000008100 Brassica rapa Species 0.000 description 2
- 235000000540 Brassica rapa subsp rapa Nutrition 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 101000835317 Mus musculus Thioredoxin Proteins 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 241000220259 Raphanus Species 0.000 description 2
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 description 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 230000005779 cell damage Effects 0.000 description 2
- 208000037887 cell injury Diseases 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 208000030533 eye disease Diseases 0.000 description 2
- 239000003889 eye drop Substances 0.000 description 2
- 229940012356 eye drops Drugs 0.000 description 2
- -1 fatty acid esters Chemical class 0.000 description 2
- QOLIPNRNLBQTAU-UHFFFAOYSA-N flavan Chemical compound C1CC2=CC=CC=C2OC1C1=CC=CC=C1 QOLIPNRNLBQTAU-UHFFFAOYSA-N 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 230000005484 gravity Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000013425 morphometry Methods 0.000 description 2
- 239000007923 nasal drop Substances 0.000 description 2
- 229940100662 nasal drops Drugs 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 2
- BOPGDPNILDQYTO-NNYOXOHSSA-N nicotinamide-adenine dinucleotide Chemical compound C1=CCC(C(=O)N)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]2[C@H]([C@@H](O)[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)O1 BOPGDPNILDQYTO-NNYOXOHSSA-N 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 210000000608 photoreceptor cell Anatomy 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000004243 retinal function Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000013042 tunel staining Methods 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- VQVUBYASAICPFU-UHFFFAOYSA-N (6'-acetyloxy-2',7'-dichloro-3-oxospiro[2-benzofuran-1,9'-xanthene]-3'-yl) acetate Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(Cl)=C(OC(C)=O)C=C1OC1=C2C=C(Cl)C(OC(=O)C)=C1 VQVUBYASAICPFU-UHFFFAOYSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- LSIXBBPOJBJQHN-UHFFFAOYSA-N 2,3-Dimethylbicyclo[2.2.1]hept-2-ene Chemical compound C1CC2C(C)=C(C)C1C2 LSIXBBPOJBJQHN-UHFFFAOYSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- XDFNWJDGWJVGGN-UHFFFAOYSA-N 2-(2,7-dichloro-3,6-dihydroxy-9h-xanthen-9-yl)benzoic acid Chemical compound OC(=O)C1=CC=CC=C1C1C2=CC(Cl)=C(O)C=C2OC2=CC(O)=C(Cl)C=C21 XDFNWJDGWJVGGN-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 235000011331 Brassica Nutrition 0.000 description 1
- 241000219198 Brassica Species 0.000 description 1
- 235000010149 Brassica rapa subsp chinensis Nutrition 0.000 description 1
- 235000000536 Brassica rapa subsp pekinensis Nutrition 0.000 description 1
- 241000499436 Brassica rapa subsp. pekinensis Species 0.000 description 1
- 241000219193 Brassicaceae Species 0.000 description 1
- 241000195940 Bryophyta Species 0.000 description 1
- 241000254173 Coleoptera Species 0.000 description 1
- 244000301850 Cupressus sempervirens Species 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 241000801434 Eruca Species 0.000 description 1
- 235000013830 Eruca Nutrition 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 206010015958 Eye pain Diseases 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 208000003098 Ganglion Cysts Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000954195 Homo sapiens Protein VAC14 homolog Proteins 0.000 description 1
- 101000852559 Homo sapiens Thioredoxin Proteins 0.000 description 1
- 241001406989 Iberis Species 0.000 description 1
- 208000006550 Mydriasis Diseases 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 235000005733 Raphanus sativus var niger Nutrition 0.000 description 1
- 240000001970 Raphanus sativus var. sativus Species 0.000 description 1
- 201000007737 Retinal degeneration Diseases 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 208000005400 Synovial Cyst Diseases 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000003986 cell retinal photoreceptor Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000007910 chewable tablet Substances 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 235000013353 coffee beverage Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 238000004042 decolorization Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000004332 deodorization Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000018927 edible plant Nutrition 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000007159 enucleation Effects 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000015203 fruit juice Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 102000056461 human TXN Human genes 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000002991 immunohistochemical analysis Methods 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 238000002843 lactate dehydrogenase assay Methods 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000021056 liquid food Nutrition 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 208000038015 macular disease Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 235000020124 milk-based beverage Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 230000003562 morphometric effect Effects 0.000 description 1
- 235000011929 mousse Nutrition 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000021095 non-nutrients Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 229920002113 octoxynol Polymers 0.000 description 1
- 239000002997 ophthalmic solution Substances 0.000 description 1
- 229940054534 ophthalmic solution Drugs 0.000 description 1
- 210000003733 optic disk Anatomy 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 150000004965 peroxy acids Chemical class 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 108091008695 photoreceptors Proteins 0.000 description 1
- 235000012015 potatoes Nutrition 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 150000003138 primary alcohols Chemical class 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 239000011814 protection agent Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 235000011962 puddings Nutrition 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004258 retinal degeneration Effects 0.000 description 1
- 230000004283 retinal dysfunction Effects 0.000 description 1
- 235000019685 rice crackers Nutrition 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000012130 whole-cell lysate Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/26—Cyanate or isocyanate esters; Thiocyanate or isothiocyanate esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- the present invention relates to a retinal protective agent that has an excellent protective action on the retina and can be used safely. Also
- the present invention relates to a pharmaceutical composition and a food or drink used for retinal protection. Furthermore, the present invention relates to a method for protecting the retina.
- Non-Patent Documents 1 and 2 It is known that chronic light exposure to sunlight or indoor lighting causes retinal photoreceptor cell damage and cell death, and is involved in the onset and exacerbation of age-related macular degeneration, retinitis pigmentosa, etc.
- Non-Patent Documents 1 and 2 It is also known that light macular disease develops due to light from a surgical microscope used in ophthalmic treatment (for example, Non-Patent Document 3).
- the retina is likely to have some damage to the retina even though it is mild due to the effects of direct sunlight, ultraviolet rays, etc., it will continue to be damaged. Risk of injury.
- Light that causes damage to the retina includes ultraviolet rays (particularly UV-A), visible light, etc.
- light with a wavelength force of S400 to 500 nm is said to have the highest degree of damage.
- white light including light with a wavelength of 400 to 800 nm is known to cause irreversible retinal damage in white mice after irradiation for 1 hour.
- Non-patent literature l Cruickshanks KJ. Et al, Arch Ophthalmol. 1993; 111: 514-8.
- Non-patent document 2 Cideciyan AV. Et al., Proc Natl Acad Sci US A. 1998; 95: 7103-8.
- Non-patent document 3 Byrnes GA. Et al., Am J Ophthalmol. 1995; 119: 231-2 .
- An object of the present invention is to provide a retinal protective agent that has an excellent protective effect on the retina and can be used safely. Another object of the present invention is to provide a pharmaceutical composition and a food or drink used for retinal protection. Furthermore, the present invention provides a method for protecting the retina. Objective.
- the present inventors have found that oral or intraperitoneal administration of sulforafuan reduces retinal damage due to excessive light irradiation.
- the present invention has been completed based on such findings.
- excessive light irradiation refers to light irradiation with an illuminance of about lOOOOlux or more.
- retinal protection by sulforafuan is thought to be because thioredoxin expression is induced by sulforafuan administration and retinal damage due to light irradiation is suppressed. .
- Retinal protective agent containing sulforafuan as an active ingredient.
- Item 2 A pharmaceutical composition for protecting the retina, comprising sulforafuan.
- Item 3 A pharmaceutical composition comprising the retinal protective agent according to Item 1.
- Item 4 The pharmaceutical composition according to Item 2, which is a preventive or therapeutic agent for retinal disorders.
- Item 5 The pharmaceutical composition according to Item 4, wherein the retinal disorder is any one selected from the group consisting of age-related macular degeneration, retinitis pigmentosa, and light macular degeneration.
- the retinal disorder is any one selected from the group consisting of age-related macular degeneration, retinitis pigmentosa, and light macular degeneration.
- Item 3 The pharmaceutical composition according to Item 2, which is ⁇ 200 mg / kg.
- Item 7 A food having a retinal protective effect, comprising sulforafuan.
- Item 8 A food having a retinal protective action, comprising the retinal protective agent according to Item 1.
- Item 10 The food according to Item 7, which is used for prevention or treatment of retinal disorders.
- Item 13 The food according to Item 12, wherein the retinal disorder is any one selected from the group consisting of age-related macular degeneration, retinitis pigmentosa, and light macular degeneration.
- Item 14 The food according to Item 7, which is in the form of powder, granule, capsule, or tablet.
- Item 15 A mammal characterized in that a mammal is administered or ingested sulforafuan. Animal retina protection method.
- Item 16 The method according to item 15, which is a method for preventing or treating retinal disorders.
- Item 17 The method according to Item 16, wherein the retinal disorder is any one selected from the group consisting of age-related macular degeneration, retinitis pigmentosa, and light macular degeneration.
- Item 18 Use of sulforan for the manufacture of retinal protection agents.
- Item 19 Use of sulfaurafuan for the manufacture of a pharmaceutical composition for retinal protection.
- FIG. 1A shows the results of Western blotting analysis of TRX in the RPE fraction (RPE fraction: upper part) and neural retinal layer (neural retina: lower part) of mice intraperitoneally administered with SF.
- FIG. 1B shows the results of specific gravity analysis for TRX bands in Western blotting analysis. The average value was calculated from the two TRX bands in each group shown in Fig. 1A and represented in a bar graph.
- FIG. 1C From control mice treated with intraperitoneal saline (Control: left panel) and SF (0.5 mg / day for 3 days; intraperitoneal administration) treated mice (SF (+): right panel) A representative example of TRX immunohistochemistry in the retina is shown. Arrow: Indicates where TRX is strongly expressed in the RPE layer of SF-treated mice.
- GCL ganglion cell 1 ayer
- INL inner nuclear layer
- ONL outer nuclear layer
- RPE retinal pigment epithelial layer
- FIG. 2A shows the results of Western blotting analysis of TRX in the RPE fraction (RPE fraction: upper part) and neural retinal layer (neural retina: lower part) of mice orally administered with SF.
- FIG. 2B shows the results of specific gravity analysis for TRX bands in Western blotting analysis. The average value was calculated from the two TRX bands in each group shown in Fig. 2A and represented in a bar graph.
- FIG. 3A Non-irradiated mice (Light (—): left panel) and retinal hematoxylin eosin from 24 hours (middle panel) and 96 hours (right panel) after light irradiation (HE) shows the results of staining.
- the upper panel is the retina of a control mouse (Control) in which saline was administered intraperitoneally (3 days) before light irradiation, and the lower panel was SF (3 days before light irradiation). It is the retina of a mouse (SF (+)) administered intraperitoneally between 0.5 mg / day.
- ONL outer nuclear layer
- RPE R
- FIG. 3B Quantification results of the number of cell nuclei in ONL (outer nuclear layer: left) and RPE (retinal pigment epithelial layer: right) are shown. Each bar graph represents the mean value person SD. P value is 7 by unpaired t-test.
- FIG. 4A shows TUNEL staining of the retina obtained from light-irradiated mice (Light (—): left panel) and 24 hours (center panel) and 96 hours (right panel) after light irradiation.
- the upper panel is the retina of a control mouse (Control) that was administered intraperitoneally with physiological saline (3 days) before light irradiation, and the lower panel received SF (0.5 mg / day for 3 days) before light irradiation. It is a retina of a mouse (SF (+)) administered intraperitoneally.
- FIG. 4B Quantification results of TUNEL positive cell nuclei in ONL (outer nuclear layer: left) and RPE (retinal pigment epithelial layer: right) are shown as percentages. Each bar graph represents the mean SD. P value was calculated by unpaired t-test.
- FIG. 5A Before irradiation of mice (Control) intraperitoneally administered with saline prior to light irradiation and mice (SF (+)) administered intraperitoneally with SF (0.5 mg / day) for 3 days before light irradiation A typical example of ERG recording after light irradiation is shown.
- FIG. 5B Quantification results of a-wave (a-wave: left) and b-wave (b-wave: right) amplitudes are shown. Each bar dull represents the average valuator SD. P value was calculated by unpaired t-test.
- FIG. 6 K-1034 cells Representative examples of Western blotting analysis results in RPE cells.
- FIG. 7 shows the results of LDH release assay in SF-10-treated K-1034 cells.
- FIG. 8 shows measurement results of intracellular peroxidase production.
- DCFH (-) represents a cell after treatment with a peroxide-sensitive fluorescent probe.
- retinal protection means suppression of retinal disorders, particularly retinal disorders such as visual loss, visual field stenosis, and blindness due to light irradiation-induced retinal degeneration.
- the retinal protective agent of the present invention is characterized by containing sulforafuan as an active ingredient.
- the sulforan is not limited to isolated sulforan.
- the plant containing sulforafuan, pulverized product of the plant, freeze-dried product of the plant, juice of the plant, extract of the plant, etc. (Sometimes referred to as “sulforafuan-containing”).
- Examples of plants that contain sulfaurauan include plants of the Brassicaceae plant, such as Brassica, Eruca, Iberis, and Rapha nus. .
- Specific examples of the plant include cabbage, purple beetle, broccoli, kale, rocket vegetable, cauliflower, Japanese radish, Chinese cabbage, turnip, and komatsuna.
- Chingensai and the like are exemplified.
- the shoots of these plants are preferably used in the present invention where the content of sulforafuan is high.
- the parts having a high content of sulfaurafuan include the seeds of the plants; the roots of radish, turnip, etc .; the leaves of cabbage, kale, rooster, cypress; the florets of broccoli, cauliflower, etc. Desirable to use these plant parts, mentioned.
- the sulforafuan content of the shoots varies greatly depending on the number of days after germination, and therefore it is desirable to use shoots with a high sulforafuan content.
- the sulforafuan content of the shoots varies greatly depending on the number of days after germination, and therefore it is desirable to use shoots with a high sulforafuan content.
- the pulverized product, lyophilized product, and juice of a plant containing sulforafuan can be obtained by treating the plant with a treatment method usually used by those skilled in the art.
- a plant extract containing sulforafuan can be obtained from the above-mentioned plants by an extraction treatment method usually used by those skilled in the art.
- the extraction processing method is not particularly limited.
- the raw material containing sulforafuan such as broccoli.
- a method of pulverizing, lyophilizing as necessary, and impregnating or extracting with water or a water-containing solvent can be mentioned.
- the solvent used for the extraction is not particularly limited.
- lower alkyl esters such as: hydrocarbons such as benzene and hexane; acetone; a conventionally known solvent such as methylene chloride, or a mixed solution thereof.
- preferred solvents are water, ethanol or a mixed solution of ethanol and water.
- supercritical such as supercritical CO
- the number of extractions may be single or multiple, in order to increase the yield.
- self-digestion may be performed after grinding the raw material for the purpose of efficiently obtaining sulforafuan by hydrolyzing dalcosinolate with an enzyme contained in the plant. Self-digestion may be performed under conditions normally used by those skilled in the art, but it is desirable to perform the digestion at about 10-50 ° C for about 15-60 minutes, for example.
- the extract thus obtained can be used as it is as a sulforan-containing plant extract, but is further subjected to a purification step such as deodorization and decolorization within a range not losing the effects of the present invention. May be.
- the extract may be subjected to a separation / purification step such as a treatment with a synthetic adsorbent, a filtration treatment, a concentration treatment, etc., if necessary, so as to increase the sulfuraguan content ratio.
- the treatment method using the synthetic adsorbent is not particularly limited, and a conventionally known method may be used.
- the synthetic adsorbent is passed through a column packed with the synthetic adsorbent, and is eluted with water, ethanol, or a mixed solution thereof.
- the elution method is mentioned.
- synthetic adsorbents include aromatic (cross-linked styrene) synthetic adsorbents, substituted aromatic synthetic adsorbents, and acrylic synthetic adsorbents.
- a sulfaurauan-containing plant extract is obtained in a liquid form, and a water-soluble dietary fiber such as pectin or dextrin is added to the extract as an excipient, and a known method such as a spray drying method is used.
- the sulfaurauan-containing plant extract may be prepared in powder form. Further, this powdery extract can be used by re-dissolving in a solvent such as water, ethanol, propylene glycol, 1,3-butylene glycol, glycerin and the like.
- a solvent such as water, ethanol, propylene glycol, 1,3-butylene glycol, glycerin and the like.
- a plant extract containing sulforafuan, particularly a dried product thereof, is used. It is expected to improve the stability of sulforan.
- the sulforaphan-containing material is preferably about 0.001 to 200 mg / g of sulforan. It is desirable to contain about 0.005 to 80 mg / g, more preferably about 0.01 to 50 mg / g.
- sulforan can be obtained by isolation and purification by the above-mentioned known methods of plant power containing sulforan.
- the isolated and purified sulforaphane is commercially available, and a commercially available product can also be used.
- the retinal protective agent of the present invention may be the above-mentioned sulforaphane itself, or may be formulated by appropriately mixing an appropriate base material or carrier.
- the retinal protective agent of the present invention is applied to mammals (including humans) that are required to protect the retina in various forms such as internal use, ingestion, injection, infusion, transmucosal administration, etc.
- mammals including humans
- the mammal effectively exerts a protective action on the retina.
- the application amount (intake or administration) of the retinal protective agent of the present invention can be appropriately set according to the application form as long as it is an effective amount that exerts a protective action on the retina.
- the amount applied includes the usage, the subject's age, sex, weight, health condition, other conditions, symptoms
- the amount of sulforafuan, which is an active ingredient, is usually selected depending on the degree of sulforan, etc.1S adult 1 sulforan as per day, preferably about 0.001 to 200 mg / kg, preferably about 0.1 to 50 mg / kg, more preferably 2 to 20 mg / It is desirable to set it to approximately kg.
- the application amount per day may not be applied every day, for example, it may be applied every 2 to 3 days, or it may be applied every other week.
- continuous administration or ingestion is preferred to maintain the retinal protective effect.
- the daily dose may be applied once, or may be divided into several times.
- the application amount thereof includes the usage, age, sex, health condition, other conditions, degree of symptoms, etc.
- the amount of sulforafuan as an active ingredient is about 0.05 to 2000 mg, preferably about 0.5 to 500 mg as sulforan per 1 adult. Degree, more preferably 2 to: It is desirable to set to about LOOmg.
- the application amount per day may be applied every 2 to 3 days instead of every day, or every other week.
- the application amount per day may be applied once, or may be applied in about 2 to 6 times a day.
- the retinal protective agent of the present invention is used in fields such as medicine and food. That is, by preparing a pharmaceutical composition or food using the retinal protective agent of the present invention, a pharmaceutical composition or food exhibiting a retinal protective effect is provided.
- a pharmaceutical composition or food exhibiting a retinal protective effect is provided.
- a pharmaceutical composition for retinal protection is provided by blending a pharmaceutically acceptable carrier together with an amount of sulforafuan effective for retinal protection.
- Carriers to be blended in the pharmaceutical composition for retinal protection include binders, disintegrants, surfactants, absorption enhancers, humectants, adsorbents, lubricants, fillers, extenders, and the like.
- Illustrative examples include wetting agents, preservatives, stabilizers, emulsifiers, solubilizers, diluents or excipients such as salts for adjusting osmotic pressure, buffering agents, etc., which are appropriately selected according to the dosage unit form of the resulting preparation. used.
- the retinal protective pharmaceutical composition may contain additives such as coloring agents, preservatives, fragrances, flavoring agents, sweetening agents, and other pharmacologically active ingredients as necessary.
- the pharmaceutical composition for protecting the retina is an internal preparation; injection such as intravenous injection, subcutaneous injection, intradermal injection, intramuscular injection and intraperitoneal injection; instillation; transmucosal such as eye drops and nasal drops Used in the form of pharmaceutical preparations.
- the dosage form of the pharmaceutical composition for protecting the retina is appropriately set according to the application form.
- solid preparations such as tablets, powders, powders, granules, capsules, etc .
- liquids, emulsions And liquid preparations such as suspensions.
- the pharmaceutical composition for protecting the retina is an injection such as a solution, emulsion, suspension, etc.
- these are preferably sterilized and formulated into these dosage forms that are preferably isotonic with blood.
- blood For example, water, ethyl alcohol, macrogol, propylene glycol, ethoxylated isostearyl alcohol, polyoxylated isostearyl alcohol, polyoxyethylene sorbitan fatty acid esters and the like can be used as a diluent.
- isotonic A sufficient amount of sodium chloride, glucose, or glycerin to prepare a neutral solution may be contained in the drug of the present invention. Ordinary solubilizers, buffers, soothing agents, etc. may be added.
- the pharmaceutical composition for protecting the retina when it is a liquid preparation, it may be stored in a state such as cryopreservation or freeze-drying. If the product is freeze-dried, add distilled water for injection at the time of use and dissolve it again before use.
- the content ratio of sulforafuan in the pharmaceutical composition for retinal protection can be appropriately adjusted according to the daily application amount of the above-mentioned retinal protective agent, the dosage form of the composition, the administration form, and the like.
- the pharmaceutical composition for retinal protection is a transmucosal preparation such as eye drops or nasal drops
- sulforafuan is contained in the preparation in an amount of 0.001 to wt%, preferably 0.01 to 5%.
- a proportion by weight, more preferably 0.05-2.5% by weight, is exemplified.
- the pharmaceutical composition for retinal protection exhibits an excellent retinal protective effect, the agent for the prevention or treatment of eye diseases caused by retinal disorders such as age-related macular degeneration, retinitis pigmentosa, and photomacular disease Useful as.
- the pharmaceutical composition for protecting the retina protects the retina from excessive light irradiation power associated with ophthalmic surgery because the active ingredient sulforaphane induces thioredoxin and suppresses light-induced retinal damage. It is also possible to use for this purpose.
- the pharmaceutical composition for retinal protection may be continuously administered for about 1 to 10 days, preferably about 2 to 6 days, more preferably about 3 to 4 days before surgery. Are preferred.
- the pharmaceutical composition for protecting the retina is also useful as an agent for preventing or reducing eye strain caused by light irradiation.
- Eye strain includes blurred vision, eye pain, and decreased ability to adjust focus. In particular, it is effective against eye strain caused by exposure to light, such as using a personal computer, reading, and working in hot weather.
- foods having a retina protective action can be provided by blending sulforafuan as a component into foods.
- Examples of the food include foods and drinks such as dietary supplements, non-nutrient nutritional foods, health foods, nutritional functional foods, foods for specified health use, and foods for the sick. Made of these foods The production method is not particularly limited as long as a retinal protective effect can be obtained.
- Suitable examples of the food include supplements having the form of powder, granules, capsules, tablets and the like.
- sulfaurafuan preferably a pulverized plant containing sulforaphane, a freeze-dried product of the plant, a juice of the plant, or an extract of the plant, more preferably the plant Extract is used.
- the food includes gum, candy, gummi, tablet confectionery, cookies, cake, chocolate, ice cream, jelly, mousse, pudding, biscuits, corn flakes, chewable tablets, wafers, rice crackers, etc. Sweets; carbonated drinks, soft drinks, milk drinks, coffee drinks, tea drinks, fruit juice drinks, nutrition drinks, alcoholic drinks, mineral water, and other drinks; Seasonings such as breads, potatoes, kamaboko and other kneaded products, sprinkles and the like.
- the oral intake form it may be in the form of tube intake (liquid food, etc.)!
- the content of sulforafuan in the food can be appropriately adjusted according to the daily application amount of the above-mentioned retinal protective agent, the form of the food, etc.
- the total amount of the food, Surufuorafuan is 0.005 to 10 weight 0/0, preferably from 0.01 to 2.5 wt%, are exemplified proportion more preferably a 05 to 1% by weight 0.1.
- the retinal protective action it may be provided as a food having a high sulfur flavan content.
- the ratio used as a sulfa fluor anchor for example, 20 weight% or more with respect to the total amount of foodstuffs, Preferably it is 30 to 70 weight%.
- the food has a retinal protective action, and is useful as a food for the prevention or treatment of eye diseases caused by retinal disorders such as age-related macular degeneration, retinitis pigmentosa, and photomacular degeneration. It is for.
- the food can also be used for the purpose of protecting the retina with an excessive light irradiation power associated with ophthalmic surgery as in the case of the pharmaceutical composition.
- the method for ingesting the food in this case is the same as in the case of the pharmaceutical composition.
- the food has a retinal protective action, and is useful as a food for preventing or reducing eye strain caused by light irradiation.
- the subject eye strain is the same as in the case of the pharmaceutical composition.
- the present invention further provides a method for protecting a mammal's retina, which comprises administering or ingesting an effective amount of sulforafuan to a mammal in which protection of the retina is desired.
- the mammal includes a human.
- sulforan used, the administration or intake effective amount thereof, the number of administration or application per day, etc. are as described above.
- this method is useful as a method for preventing or treating retinal disorders such as age-related macular degeneration, retinitis pigmentosa, and photomacular degeneration.
- this method is useful as a method for preventing or reducing eye strain caused by light irradiation.
- Usagi anti-mouse TRX antibody and mouse anti-human antibody used for Western blotting analysis and immunohistochemical staining are those described in Tanito M. et al, Neurosci Lett. 2002; 326: 142-6 did.
- mice were purchased from Japan SLC and raised in a breeding room for 5-7 days before the test.
- the light intensity in the breeding room was 300 lux
- the light intensity in the breeding cage was 20-40 lux. All mice were housed on a 12 hour (8am to 8pm) light Z cycle.
- SF sulforan used in the examples of the present invention was purchased from LTK laboratories Inc. (product number: S8046).
- 0.1 or 0.5 mg of SF dissolved in 100 1 physiological saline is injected into a mouse using a 1 ml syringe, and this operation is performed once a day until 5 days. It was.
- 0.5 mg of SF dissolved in 25 1 physiological saline was administered using a micropipette, and this operation was performed once a day until 7 days. All medications were administered at 10 am.
- retinal samples neural retina and RPE (retinal pigmented epithelium) cell fraction
- Western blotting methods are described in Tanito M. et al., Invest Ophthalmol Vis Sci. 2002; 43: 1162-7. Both eyes of each mouse were stored and used for analysis. Electrophoresis was performed on 15% sodium dodecyl sulfate (SDS) -polyacrylamide gel using an equal amount of retinal protein (5 ⁇ g). Band images were analyzed using NIH image software. For the analysis, samples with the strength of two mice in each group were used.
- SDS sodium dodecyl sulfate
- mice were also perfused with PBS, left ventricular force, and then with 4% paraformaldehyde containing freshly prepared 0.25% dartal aldehyde (PBS).
- a silk suture (A7-0) was placed on the temporal region of the right eye, and then the right eye was removed.
- the eyeball was embedded in paraffin, and sagittal sections (thickness 1 ⁇ m) of the entire retina including the optic disc were prepared.
- mice were treated with SF (0.5 mg / day) or saline for 3 days, and irradiated with light 24 hours after the last SF or saline administration. All light irradiation occurred at 10 am. Twenty-four hours before this experiment, the mice were dark-synchronized, and 1% cyclopentartrate ophthalmic solution (manufactured by Santen Pharmaceutical Co., Ltd.) was administered 1 hour before light irradiation to cause mydriasis. Anesthesia! /, Na!
- mice are irradiated with fluorescent white light (made by Matsushita Electric Industrial Co., Ltd.) of 6000 lux (including light of 400-800 nm) for 2 hours in a breeding cage where the inside reflects light did.
- fluorescent white light made by Matsushita Electric Industrial Co., Ltd.
- 6000 lux including light of 400-800 nm
- the room temperature during light irradiation was kept at 25 ⁇ 1.5 ° C, and the mice were kept in the dark until recording electroretinogram (sometimes referred to as ERG) and enucleation.
- ERG electroretinogram
- hematoxylin-eosin H-E
- a digitized color image of 4 power points in total, 2 power points from the retina 100-800 / ⁇ ⁇ above the optic disc and 2 power points from the retina 100-800 m below the optic nerve head It was obtained using a PDMC le digital imaging system (manufactured by Olympus Corporation). The number of hematoxylin positive photoreceptor nuclei and RPE cell nuclei in each image was counted and compared between saline-treated mice and SF-treated mice.
- TUNEL staining 96 hours after the light irradiation, the right eye was removed and TUNEL assembly was performed on the obtained section using an in situ Apoptosis Detection Kit (manufactured by Takara Bio Inc.). 3 ', 3'-Diamaminobenzidine (DAKO, Canada) was used as the chromogen.
- the percentages of TUNEL positive light-receiving cell nuclei (ONL) and RPE cell nuclei were measured at the same site as the morphometric site and compared between saline-treated and SF-treated mice.
- TUNEL positive cells were compared to mice injected with physiological saline, and the direction of the mice injected with SF before light irradiation was 24 hours and 96 hours after light irradiation in ONL, and light irradiation in the RPE layer. After 96 hours, there was a marked decrease in power ( Figures 4A and 4B).
- ERG was recorded to measure retinal function after 96 hours of light irradiation.
- a left-eye flash ERG was recorded according to the method described in Tanito M. et al., Invest Ophthalmol Vis Sci. 2002; 43: 2392-400. (PE-300, manufactured by Tome Co., Ltd.) ). Saline treated mouse (control) and SF treated mouse forces The average of the a-wave and b-wave amplitudes obtained was compared.
- the a-wave represents the activity of photoreceptor cells (cone and rod cells), and the b-wave represents the activity of bipolar and Muller cells.
- the amplitudes of a- and b-waves reflect retinal function, and the stronger the retinal dysfunction, the lower these amplitudes.
- TRX induction by SF was analyzed using K-1034 cells.
- Human K-1034RPE cells were maintained in Ham's F-12 medium containing 10% fetal bovine serum, 100 units / ml penicillin and 100 ⁇ g / ml streptomycin, 5% CO, 37 ° C.
- K-1034 cells (5 x 10 5 cells) are cultured in 10 ml of medium on a 10 cm culture dish, 48 hours SF (1 ⁇ M) treatment was performed until the end.
- a lysate of whole cells was prepared as described in Takagi Y. et al, Proc Natl Acad Sci US A. 1999; 96: 413 1-6.
- An equal volume of whole cell lysate (5 g) was electrophoresed on a 15% SDS polyacrylamide gel. Thereafter, a specific band was detected according to the method described in Tanito M. et a 1., Invest Ophthalmol Vis Sci. 2002; 43: 1162-7.
- TRX is known to be induced by various types of stress such as oxidative stress, the cytotoxicity and the amount of intracellular peroxide after SF treatment were measured.
- K-1034 cells (1 ⁇ 10 4 cells) were cultured in 0.2 ml medium on 96-well culture plates and treated with SF (1 or 10 M) or H 0 (200 ⁇ ⁇ ). 50 ⁇ l culture after incubation
- LDH lactate dehydrogenase
- NADH reduced nicotinamide adeninedinucleotide
- K-1034 cells (5 ⁇ 10 5 cells) were cultured on a 10 cm culture dish using 10 ml medium, and treated with SF (1 or 10 ⁇ ) for 24 hours or ⁇ 0 (200 ⁇ ) for 3 hours. The cells are then
Abstract
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006535228A JPWO2006030907A1 (ja) | 2004-09-16 | 2005-09-16 | 網膜保護剤 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004-270424 | 2004-09-16 | ||
JP2004270424 | 2004-09-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006030907A1 true WO2006030907A1 (ja) | 2006-03-23 |
Family
ID=36060154
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/017170 WO2006030907A1 (ja) | 2004-09-16 | 2005-09-16 | 網膜保護剤 |
Country Status (2)
Country | Link |
---|---|
JP (1) | JPWO2006030907A1 (ja) |
WO (1) | WO2006030907A1 (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007302633A (ja) * | 2006-05-12 | 2007-11-22 | Redox Bioscience Inc | 繊維質の燃焼時に発生する煙に含まれる有害成分によって引き起こされる障害の予防乃至治療剤 |
JP2007302577A (ja) * | 2006-05-09 | 2007-11-22 | National Agriculture & Food Research Organization | 茶葉抽出組成物 |
WO2018066707A1 (ja) * | 2016-10-07 | 2018-04-12 | 株式会社 Pal | 老化抑制剤、軟部組織の石灰化抑制剤、及び肺組織破壊抑制剤 |
JP7138934B2 (ja) | 2018-10-11 | 2022-09-20 | 学校法人常翔学園 | 網膜神経保護作用を有するアペリン受容体アゴニストを含有する医薬組成物 |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002051732A (ja) * | 2000-06-12 | 2002-02-19 | Access Business Group Llc | 食事による植物性化学物質欠乏症を矯正する組成物及び方法 |
JP2003518033A (ja) * | 1999-12-20 | 2003-06-03 | コグニス・フランス・ソシエテ・アノニム | 化粧品製剤および/または医薬製剤 |
WO2003068202A1 (en) * | 2002-02-15 | 2003-08-21 | Dsm Ip Assets B.V. | Compositions comprising lycopene for the treatment and prevention of angiogenesis associated pathologies |
JP2004514456A (ja) * | 2000-12-08 | 2004-05-20 | アクセス ビジネス グループ インターナショナル リミテッド ライアビリティ カンパニー | アブラナ科野菜組成物及びその製造方法 |
JP2004519423A (ja) * | 2000-08-21 | 2004-07-02 | ジェド ダブリュ. ファーヒー | イソチオシアネートを用いたヘリコバクターの治療方法 |
JP2005047822A (ja) * | 2003-07-30 | 2005-02-24 | Japan Research & Development Association For New Functional Foods | 高血糖障害抑制剤 |
WO2005063295A1 (en) * | 2003-12-22 | 2005-07-14 | Alcon, Inc. | Agents for treatment of glaucomatous retinopathy and optic neuropathy |
WO2005063249A1 (en) * | 2003-12-22 | 2005-07-14 | Alcon, Inc. | Agents for treatment of diabetic retinopathy and drusen formation in macular degeneration |
-
2005
- 2005-09-16 WO PCT/JP2005/017170 patent/WO2006030907A1/ja active Application Filing
- 2005-09-16 JP JP2006535228A patent/JPWO2006030907A1/ja active Pending
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003518033A (ja) * | 1999-12-20 | 2003-06-03 | コグニス・フランス・ソシエテ・アノニム | 化粧品製剤および/または医薬製剤 |
JP2002051732A (ja) * | 2000-06-12 | 2002-02-19 | Access Business Group Llc | 食事による植物性化学物質欠乏症を矯正する組成物及び方法 |
JP2004519423A (ja) * | 2000-08-21 | 2004-07-02 | ジェド ダブリュ. ファーヒー | イソチオシアネートを用いたヘリコバクターの治療方法 |
JP2004514456A (ja) * | 2000-12-08 | 2004-05-20 | アクセス ビジネス グループ インターナショナル リミテッド ライアビリティ カンパニー | アブラナ科野菜組成物及びその製造方法 |
WO2003068202A1 (en) * | 2002-02-15 | 2003-08-21 | Dsm Ip Assets B.V. | Compositions comprising lycopene for the treatment and prevention of angiogenesis associated pathologies |
JP2005047822A (ja) * | 2003-07-30 | 2005-02-24 | Japan Research & Development Association For New Functional Foods | 高血糖障害抑制剤 |
WO2005063295A1 (en) * | 2003-12-22 | 2005-07-14 | Alcon, Inc. | Agents for treatment of glaucomatous retinopathy and optic neuropathy |
WO2005063249A1 (en) * | 2003-12-22 | 2005-07-14 | Alcon, Inc. | Agents for treatment of diabetic retinopathy and drusen formation in macular degeneration |
Non-Patent Citations (2)
Title |
---|
GAO X. ET AL: "Induction of phase 2 genes by sulforaphane protects retinal pigment epithelial cells against photooxidative damage", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 101, no. 28, 13 July 2004 (2004-07-13), pages 10446 - 10451, XP002993321 * |
GAO X. ET AL: "Powerful and prolonged protection of human retinal pigment epithelial cells, keratinocytes, and mouse leukemia cells against oxidative damage: The indirect antioxidant effects of sulforaphane", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, vol. 98, no. 26, 2001, pages 15221 - 15226, XP002322402 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007302577A (ja) * | 2006-05-09 | 2007-11-22 | National Agriculture & Food Research Organization | 茶葉抽出組成物 |
JP2007302633A (ja) * | 2006-05-12 | 2007-11-22 | Redox Bioscience Inc | 繊維質の燃焼時に発生する煙に含まれる有害成分によって引き起こされる障害の予防乃至治療剤 |
WO2018066707A1 (ja) * | 2016-10-07 | 2018-04-12 | 株式会社 Pal | 老化抑制剤、軟部組織の石灰化抑制剤、及び肺組織破壊抑制剤 |
JPWO2018066707A1 (ja) * | 2016-10-07 | 2019-09-05 | 株式会社Pal | 老化抑制剤、軟部組織の石灰化抑制剤、及び肺組織破壊抑制剤 |
JP7068704B2 (ja) | 2016-10-07 | 2022-05-17 | 株式会社Pal | 老化抑制剤、軟部組織の石灰化抑制剤、及び肺組織破壊抑制剤 |
JP7138934B2 (ja) | 2018-10-11 | 2022-09-20 | 学校法人常翔学園 | 網膜神経保護作用を有するアペリン受容体アゴニストを含有する医薬組成物 |
Also Published As
Publication number | Publication date |
---|---|
JPWO2006030907A1 (ja) | 2008-05-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9511107B2 (en) | Phenolic compositions derived from apple skin and uses thereof | |
Sarialtin et al. | An overview on the role of macular xanthophylls in ocular diseases | |
JP2008528483A (ja) | 三七根、熟地黄、五加皮の混合生薬材抽出物及びそれを有効成分とする関節炎予防及び治療用組成物 | |
KR101695848B1 (ko) | 진세노사이드 f2를 포함하는 비알코올성 간 질환 또는 인슐린 저항성의 예방 또는 치료용 조성물 | |
JPWO2006033351A1 (ja) | チオレドキシン発現誘導用組成物 | |
KR100877371B1 (ko) | 시력 보호용 조성물 | |
WO2006030907A1 (ja) | 網膜保護剤 | |
EP3634456B1 (en) | Composition for use in treating retinal diseases | |
JP2007055903A (ja) | 眼血管血流障害改善剤 | |
JP2007269631A (ja) | 中性脂肪蓄積抑制剤 | |
JP2020502277A (ja) | ナマコ抽出物を有効成分とするブルッフ膜機能の低下関連病気の予防および治療用組成物 | |
AU2009219468B2 (en) | Use of black soybean for treating ophthalmic diseases | |
JP7106340B2 (ja) | 血液脳関門保護剤 | |
JP5187935B2 (ja) | 羅漢果エキスを含有する創傷治癒促進組成物と適用方法 | |
KR101835227B1 (ko) | 서목태 추출물을 포함하는 안질환 예방 또는 치료용 조성물 | |
JP2009107945A (ja) | 視神経障害抑制剤及びそれを含有する飲食品 | |
CN109481481B (zh) | 一种柳叶蜡梅总黄酮提取物的制备方法及其应用 | |
KR20110078524A (ko) | 인삼 열매 추출물을 함유하는 퇴행성 신경장애 치료용 조성물 | |
JP2010514752A (ja) | アラザイムを有効成分とする肝機能保護用薬学的組成物 | |
KR20240055551A (ko) | 자초 추출물을 포함하는 안질환의 예방 또는 치료용 조성물 | |
KR20240055547A (ko) | 건지황 추출물을 포함하는 안질환의 예방 또는 치료용 조성물 | |
KR20240055552A (ko) | 호박 추출물을 포함하는 안질환의 예방 또는 치료용 조성물 | |
KR20240055550A (ko) | 오미자 추출물을 포함하는 안질환의 예방 또는 치료용 조성물 | |
KR20240055548A (ko) | 구기자 추출물을 포함하는 안질환의 예방 또는 치료용 조성물 | |
KR20240055549A (ko) | 골담초 추출물을 포함하는 안질환의 예방 또는 치료용 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2006535228 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |